content: <HTML>
  <HEAD>
       <TITLE></TITLE>
  </HEAD>
  <BODY STYLE="font: 10pt Times New Roman, Times, Serif">
  
  <P STYLE="text-align: center; margin-top: 0; margin-bottom: 0"><B>As filed with the Securities and Exchange Commission on January 28, 2022</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Registration No. 333-</B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P>
  
  <!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>UNITED STATES</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SECURITIES AND EXCHANGE COMMISSION</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Washington, D.C. 20549</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>FORM S-8</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>REGISTRATION STATEMENT</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>UNDER</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>THE SECURITIES ACT OF 1933</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-variant: small-caps"><B>NeuroOne
  Medical Technologies Corporation</B></FONT></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Exact name of registrant as specified in its charter)</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>
  
  <TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
    <TR STYLE="vertical-align: top">
      <TD STYLE="width: 49%; border-bottom: black 1.5pt solid; padding: 0.25pt 0.25pt 0.75pt; font-size: 10pt; text-align: center"><B>Delaware</B></TD>
      <TD STYLE="width: 2%; padding: 0.25pt 0.25pt 1.75pt">&nbsp;</TD>
      <TD STYLE="width: 49%; border-bottom: black 1.5pt solid; padding: 0.25pt 0.25pt 0.75pt; font-size: 10pt; text-align: center"><B>27-0863354</B></TD></TR>
    <TR STYLE="vertical-align: top">
      <TD STYLE="padding: 0.25pt">
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(State or other jurisdiction of</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">incorporation or organization)</P></TD>
      <TD STYLE="padding: 0.25pt">&nbsp;</TD>
      <TD STYLE="padding: 0.25pt">
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(I.R.S. Employer</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Identification Number.)</P></TD></TR>
    <TR STYLE="vertical-align: top">
      <TD STYLE="padding: 0.25pt">&nbsp;</TD>
      <TD STYLE="padding: 0.25pt">&nbsp;</TD>
      <TD STYLE="padding: 0.25pt">&nbsp;</TD></TR>
    <TR STYLE="vertical-align: bottom">
      <TD STYLE="border-bottom: black 1.5pt solid; padding: 0.25pt 0.25pt 0.75pt; font-size: 10pt; text-align: center"><B>7599 Anagram Dr., <BR>
  Eden Prairie, MN </B></TD>
      <TD STYLE="padding: 0.25pt 0.25pt 1.75pt">&nbsp;</TD>
      <TD STYLE="border-bottom: black 1.5pt solid; padding: 0.25pt 0.25pt 0.75pt; font-size: 10pt; text-align: center"><B>55344</B></TD></TR>
    <TR STYLE="vertical-align: top">
      <TD STYLE="padding: 0.25pt; font-size: 10pt; text-align: center">(Address of principal executive offices) </TD>
      <TD STYLE="padding: 0.25pt">&nbsp;</TD>
      <TD STYLE="padding: 0.25pt; font-size: 10pt; text-align: center">(Zip code)</TD></TR>
    </TABLE>
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  <TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
    <TR STYLE="vertical-align: top">
      <TD STYLE="border-bottom: black 1.5pt solid; padding: 0.25pt 0.25pt 0.75pt">
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>NeuroOne Medical Technologies Corporation 2017
      Equity Incentive Plan</B></P></TD></TR>
    <TR STYLE="vertical-align: top">
      <TD STYLE="padding: 0.25pt; font-size: 10pt; text-align: center">(Full title of the plan)</TD></TR>
    <TR STYLE="vertical-align: top">
      <TD STYLE="padding: 0.25pt; font-size: 10pt; text-align: center">&nbsp;</TD></TR>
    <TR STYLE="vertical-align: top">
      <TD STYLE="padding: 0.25pt">
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>David Rosa</B></P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>President and Chief Executive Officer</B></P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>NeuroOne Medical Technologies Corporation</B></P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>7599 Anagram Dr.,<BR>
      Eden Prairie, MN 55344</B></P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>952-426-1383</B></P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; border-top: black 1.5pt solid">(Name, address,
      and telephone number, including area code, of agent for service)</P></TD></TR>
  </TABLE>
  
  <P STYLE="text-align: center; margin-top: 0; margin-bottom: 0">&nbsp;</P>
  
  <P STYLE="text-align: center; margin-top: 0; margin-bottom: 0"><B>Copy to:</B></P>
  
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Phillip D. Torrence, Esq.</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Emily Johns, Esq.</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Honigman LLP</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>650 Trade Center Way, Suite 200</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Kalamazoo, Michigan 49002-0402</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(269) 337-7700</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Indicate by check mark whether the registrant
  is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company.
  See the definitions of &ldquo;large accelerated filer,&rdquo; &ldquo;accelerated filer,&rdquo; &ldquo;smaller reporting company,&rdquo;
  and &ldquo;emerging growth company&rdquo; in Rule 12b-2 of the Exchange Act.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
  
  <TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
    <TR STYLE="vertical-align: top">
      <TD STYLE="width: 50%; font-size: 10pt">Large accelerated filer <FONT STYLE="font-family: Times New Roman, Times, Serif">&#9744;</FONT></TD>
      <TD STYLE="width: 50%; padding-left: 10pt; font-size: 10pt; text-indent: -10pt">Accelerated filer <FONT STYLE="font-family: Times New Roman, Times, Serif">&#9744;</FONT></TD></TR>
    <TR STYLE="vertical-align: top">
      <TD STYLE="font-size: 10pt">Non-accelerated filer <FONT STYLE="font-family: Times New Roman, Times, Serif">&#9746;</FONT></TD>
      <TD STYLE="padding-left: 10pt; font-size: 10pt; text-indent: -10pt">Smaller reporting company <FONT STYLE="font-family: Times New Roman, Times, Serif">&#9746;</FONT></TD></TR>
    <TR STYLE="vertical-align: top">
      <TD>&nbsp;</TD>
      <TD STYLE="padding-left: 10pt; font-size: 10pt; text-indent: -10pt">Emerging growth company <FONT STYLE="font-family: Times New Roman, Times, Serif">&#9744;</FONT></TD></TR>
    </TABLE>
  
  <P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If an emerging growth company, indicate by check
  mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting
  standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. <FONT STYLE="font-family: Times New Roman, Times, Serif">&#9744;</FONT></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>
  
  <!-- Field: Page; Sequence: 1 -->
      <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
      <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
      <!-- Field: /Page -->
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CALCULATION OF REGISTRATION FEE</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
    <TR STYLE="vertical-align: bottom">
      <TD STYLE="font-weight: bold; border-bottom: Black 1.5pt solid">Title of securities to be registered</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
      <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Amount to be</B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>registered(1)</B></P></TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
      <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Proposed maximum</B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>offering price</B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>per share</B></P></TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
      <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Proposed maximum</B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>aggregate offering</B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>price</B></P></TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
      <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Amount of</B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>registration</B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>fee</B></P></TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD></TR>
    <TR STYLE="vertical-align: bottom">
      <TD STYLE="font-weight: bold">Common stock, $0.001 par value per share</TD><TD>&nbsp;</TD>
      <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
      <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
      <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
      <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD></TR>
    <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
      <TD STYLE="width: 52%; text-align: left; text-indent: -9pt; padding-left: 9.25pt">NeuroOne Medical Technologies Corporation 2017 Equity Incentive Plan(2)</TD><TD STYLE="width: 1%">&nbsp;</TD>
      <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">1,616,873</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
      <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">1.94</TD><TD STYLE="width: 1%; text-align: left">(3)</TD><TD STYLE="width: 1%">&nbsp;</TD>
      <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">3,136,733.62</TD><TD STYLE="width: 1%; text-align: left">(3)</TD><TD STYLE="width: 1%">&nbsp;</TD>
      <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">290.78</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
    </TABLE>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  <TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
    <TR STYLE="vertical-align: top">
      <TD STYLE="width: 24px; font-size: 10pt; text-align: justify">(1)</TD>
      <TD STYLE="font-size: 10pt; text-align: justify">Pursuant to Rule 416(a) promulgated under the Securities Act of 1933, as amended, (the <B><I>&ldquo;Securities Act&rdquo;</I></B>), this Registration Statement shall also cover any additional shares of Registrant&rsquo;s common stock that become issuable under the plan set forth herein by reason of any stock dividend, stock split, reclassification, recapitalization, spin-off or other similar transaction effected without receipt of consideration that increases the number of outstanding shares of Registrant&rsquo;s common stock, as applicable.</TD></TR>
    <TR STYLE="vertical-align: top">
      <TD STYLE="font-size: 10pt; text-align: justify">&nbsp;</TD>
      <TD STYLE="font-size: 10pt; text-align: justify">&nbsp;</TD></TR>
    <TR STYLE="vertical-align: top">
      <TD STYLE="font-size: 10pt; text-align: justify">(2)</TD>
      <TD STYLE="font-size: 10pt; text-align: justify">Represents shares of common stock available for future issuance under the Registrant&rsquo;s 2017 Equity Incentive Plan.</TD></TR>
    <TR STYLE="vertical-align: top">
      <TD STYLE="font-size: 10pt; text-align: justify">&nbsp;</TD>
      <TD STYLE="font-size: 10pt; text-align: justify">&nbsp;</TD></TR>
    <TR STYLE="vertical-align: top">
      <TD STYLE="font-size: 10pt; text-align: justify">(3)</TD>
      <TD STYLE="font-size: 10pt; text-align: justify">Estimated solely for the purpose of calculating the amount of the registration fee pursuant to Rule 457(c) and Rule 457(h) under the Securities Act. The offering price per share and aggregate offering price are based on the average of the high and low prices of the Registrant&rsquo;s common stock as reported on the Nasdaq Capital Market on January 26, 2022.</TD></TR>
    </TABLE>
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>
  
  <!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>
  
  <!-- Field: Page; Sequence: 2 -->
      <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
      <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
      <!-- Field: /Page -->
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>EXPLANATORY NOTE</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This Registration Statement on Form&nbsp;S-8&nbsp;is
  being filed by NeuroOne Medical Technologies Corporation, a Delaware corporation (the <B><I>&ldquo;Company,&rdquo; </I></B>the <B><I>&ldquo;Registrant</I></B>,<B><I>&rdquo;
  &ldquo;we</I></B>,<B><I>&rdquo; &ldquo;us</I></B>,<B><I>&rdquo; or &ldquo;our&rdquo;</I></B>), relating to 1,616,873 shares of its common
  stock, par value $0.001 per share (the <B><I>&ldquo;Common Stock&rdquo;</I></B>), issuable pursuant to the 2017 Equity Incentive Plan
  (the &ldquo;<B><I>2017 Equity Incentive Plan</I></B>&rdquo;). The Common Stock being registered hereunder is in addition to the (i) 1,300,000
  shares of Common Stock registered on the Registrant&rsquo;s&nbsp;Form&nbsp;S-8&nbsp;previously filed with the Securities and Exchange
  Commission (the &ldquo;<B><I>Commission</I></B>&rdquo;) on <A HREF="http://www.sec.gov/Archives/edgar/data/1500198/000121390018005312/fs82018_neuroonemedical.htm">May 1, 2018</A>&nbsp;(Commission File&nbsp;No. 333-224572)&nbsp;and (ii) 1,079,835
  shares of Common Stock registered on the Registrant&rsquo;s&nbsp;Form&nbsp;S-8&nbsp;previously filed with the Commission on <A HREF="http://www.sec.gov/Archives/edgar/data/1500198/000121390021061596/ea149373-s8_neuroonemedical.htm">November 23, 2021</A>&nbsp;(Commission File&nbsp;No. 333-261302)&nbsp;(collectively, the &ldquo;<B><I>Prior Registration Statements</I></B>&rdquo;).</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">This Registration Statement relates to securities
  of the same class as that to which the Prior Registration Statements relate, and is submitted in accordance with General Instruction E
  to Form&nbsp;S-8&nbsp;regarding the registration of additional securities. Pursuant to such instruction, the contents of the Prior Registration
  Statements are incorporated herein by reference and made part of this Registration Statement, except as amended hereby.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"></P>
  
  <!-- Field: Page; Sequence: 3 -->
      <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
      <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
      <!-- Field: /Page -->
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>PART II</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>INFORMATION REQUIRED IN THE REGISTRATION STATEMENT</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Item 3. Incorporation of Documents by Reference.</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pursuant to General Instruction
  E to Form S-8, the contents of the Prior Registration Statements are incorporated herein by reference.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following documents filed
  with the Commission by the Registrant are hereby incorporated by reference in this Registration Statement:</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
  <TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">(a)</TD><TD STYLE="text-align: justify">our Annual Report on Form 10-K for the year ended September
  30, 2021 filed with the Commission on <A HREF="http://www.sec.gov/ix?doc=/Archives/edgar/data/1500198/000121390021065463/f10k2021_neuroone.htm">December&nbsp;15,&nbsp;2021</A>;</TD>
  </TR></TABLE>
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
  <TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">(b)</TD><TD STYLE="text-align: justify">our Current Reports on Form 8-K filed with the Commission
  on <A HREF="http://www.sec.gov/ix?doc=/Archives/edgar/data/1500198/000101376221000094/ea148325-8k_neuroone.htm">October 4, 2021</A> and <A HREF="http://www.sec.gov/ix?doc=/Archives/edgar/data/1500198/000121390021052752/ea148799-8k_neuroone.htm">October 14, 2021</A>; and</TD>
  </TR></TABLE>
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
  <TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">(c)</TD><TD STYLE="text-align: justify">the description of our Common Stock in our registration statement
  on <A HREF="http://www.sec.gov/Archives/edgar/data/1500198/000121390021028934/ea141508-8a12b_neuroone.htm">Form 8-A</A> filed with the SEC on May&nbsp;25,&nbsp;2021 and as amended by any subsequent amendment or report filed for the purpose of updating
  such description.</TD>
  </TR></TABLE>
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, all documents
  the Registrant subsequently files pursuant to Sections 13(a), 13(c), 14 or 15(d) of the Securities Exchange Act of 1934, as amended (the
  <B><I>&ldquo;Exchange Act&rdquo;</I></B>), after the filing of this Registration Statement and prior to the filing of a post-effective
  amendment which indicates that all securities offered hereby have been sold or which deregisters all securities covered hereby then remaining
  unsold are incorporated by reference in this Registration Statement and are a part hereof from the date of filing of such documents. Notwithstanding
  anything herein, the Registrant is not incorporating by reference any information furnished under Item 2.02 or Item 7.01 of any Current
  Report on Form 8-K, unless, and to the extent, specified in any such Current Report on Form 8-K.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Any statement herein or contained
  in a document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded for purposes
  of this Registration Statement to the extent that a statement contained herein, or in any subsequently filed document, which also is or
  is deemed to be incorporated by reference herein, modifies or supersedes such prior statement. Any such statement so modified or superseded
  shall not be deemed, except as so modified or superseded, to constitute part of this Registration Statement.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>
  
  <!-- Field: Page; Sequence: 4; Options: NewSection; Value: 1 -->
      <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></P></DIV>
      <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
      <!-- Field: /Page -->
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Item 8. Exhibits.</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>EXHIBIT INDEX</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following exhibits are filed as part of this
  registration statement.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>INDEX TO EXHIBITS</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>
  
  <TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse">
    <TR>
      <TD STYLE="vertical-align: bottom; width: 9%; border-bottom: black 1.5pt solid; padding: 0.25pt 0.25pt 0.75pt">
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Exhibit</B></P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Number</B></P></TD>
      <TD STYLE="width: 1%; padding: 0.25pt">&nbsp;</TD>
      <TD STYLE="vertical-align: bottom; width: 90%; border-bottom: black 1.5pt solid; padding: 0.25pt 0.25pt 0.75pt; font-size: 10pt; text-align: center"><B>Description</B></TD></TR>
    <TR STYLE="background-color: #CCEEFF">
      <TD STYLE="vertical-align: top; padding: 0.25pt; font-size: 10pt">4.1</TD>
      <TD STYLE="padding: 0.25pt">&nbsp;</TD>
      <TD STYLE="vertical-align: bottom; padding: 0.25pt 0.25pt 1pt; font-size: 10pt; text-align: justify"><A HREF="http://www.sec.gov/Archives/edgar/data/1500198/000114420417034948/v470040_ex3-4.htm">Certificate of Incorporation of NeuroOne Medical Technologies Corporation (incorporated by reference to Exhibit 3.4 on the Registrant&rsquo;s Current Report on Form 8-K filed on June, 29, 2017)</A></TD></TR>
    <TR>
      <TD STYLE="vertical-align: top; padding: 0.25pt">&nbsp;</TD>
      <TD STYLE="padding: 0.25pt">&nbsp;</TD>
      <TD STYLE="vertical-align: bottom; padding: 0.25pt">&nbsp;</TD></TR>
    <TR STYLE="background-color: #CCEEFF">
      <TD STYLE="vertical-align: top; padding: 0.25pt; font-size: 10pt">4.2</TD>
      <TD STYLE="padding: 0.25pt">&nbsp;</TD>
      <TD STYLE="vertical-align: bottom; padding: 0.25pt 0.25pt 1pt; font-size: 10pt; text-align: justify"><A HREF="http://www.sec.gov/Archives/edgar/data/1500198/000121390021018989/ea138690ex3-1_neuroone.htm">Certificate of Amendment to Amended and Restated Certificate of Incorporation of NeuroOne Medical Technologies Corporation (incorporated by reference to Exhibit 3.1 on the Registrant&rsquo;s Current Report on Form 8-K filed on March 31, 2021)</A></TD></TR>
    <TR>
      <TD STYLE="vertical-align: top; padding: 0.25pt">&nbsp;</TD>
      <TD STYLE="padding: 0.25pt">&nbsp;</TD>
      <TD STYLE="vertical-align: bottom; padding: 0.25pt">&nbsp;</TD></TR>
    <TR STYLE="background-color: #CCEEFF">
      <TD STYLE="vertical-align: top; padding: 0.25pt; font-size: 10pt">4.3</TD>
      <TD STYLE="padding: 0.25pt">&nbsp;</TD>
      <TD STYLE="vertical-align: top; padding: 0.25pt 0.25pt 1pt; font-size: 10pt; text-align: justify"><A HREF="http://www.sec.gov/Archives/edgar/data/1500198/000114420417034948/v470040_ex3-5.htm">Bylaws of NeuroOne Medical Technologies Corporation (incorporated by reference to Exhibit 3.5 on the Registrant&rsquo;s Current Report on Form 8-K filed on June 29, 2017)</A></TD></TR>
    <TR>
      <TD STYLE="vertical-align: top; padding: 0.25pt">&nbsp;</TD>
      <TD STYLE="padding: 0.25pt">&nbsp;</TD>
      <TD STYLE="vertical-align: bottom; padding: 0.25pt">&nbsp;</TD></TR>
    <TR STYLE="background-color: #CCEEFF">
      <TD STYLE="vertical-align: top; padding: 0.25pt; font-size: 10pt">4.4&dagger;</TD>
      <TD STYLE="padding: 0.25pt">&nbsp;</TD>
      <TD STYLE="vertical-align: bottom; padding: 0.25pt 0.25pt 1pt; font-size: 10pt; text-align: justify"><A HREF="http://www.sec.gov/Archives/edgar/data/1500198/000114420417021319/v464727_def14c.htm">2017 Equity Incentive Plan (incorporated by reference to Appendix G to Schedule 14C filed on April 20, 2017).</A></TD></TR>
    <TR>
      <TD STYLE="vertical-align: top; padding: 0.25pt">&nbsp;</TD>
      <TD STYLE="padding: 0.25pt">&nbsp;</TD>
      <TD STYLE="vertical-align: bottom; padding: 0.25pt">&nbsp;</TD></TR>
    <TR STYLE="background-color: #CCEEFF">
      <TD STYLE="vertical-align: top; padding: 0.25pt; font-size: 10pt">5.1</TD>
      <TD STYLE="padding: 0.25pt">&nbsp;</TD>
      <TD STYLE="vertical-align: bottom; padding: 0.25pt 0.25pt 1pt; font-size: 10pt; text-align: justify"><A HREF="ea154559ex5-1_neuroonemedi.htm">Opinion of Honigman LLP</A></TD></TR>
    <TR>
      <TD STYLE="vertical-align: top; padding: 0.25pt">&nbsp;</TD>
      <TD STYLE="padding: 0.25pt">&nbsp;</TD>
      <TD STYLE="vertical-align: bottom; padding: 0.25pt">&nbsp;</TD></TR>
    <TR STYLE="background-color: #CCEEFF">
      <TD STYLE="vertical-align: top; padding: 0.25pt; font-size: 10pt">23.1</TD>
      <TD STYLE="padding: 0.25pt">&nbsp;</TD>
      <TD STYLE="vertical-align: bottom; padding: 0.25pt 0.25pt 1pt; font-size: 10pt; text-align: justify"><A HREF="ea154559ex23-1_neuroonemedi.htm">Consent of BDO USA, LLP</A></TD></TR>
    <TR STYLE="background-color: Transparent">
      <TD STYLE="vertical-align: top; padding: 0.25pt; font-size: 10pt">&nbsp;</TD>
      <TD STYLE="padding: 0.25pt; font-size: 10pt; text-align: justify">&nbsp;</TD>
      <TD STYLE="vertical-align: bottom; padding: 0.25pt 0.25pt 1pt; font-size: 10pt; text-align: justify">&nbsp;</TD></TR>
    <TR STYLE="background-color: #CCEEFF">
      <TD STYLE="vertical-align: top; padding: 0.25pt; font-size: 10pt">23.2</TD>
      <TD STYLE="padding: 0.25pt; font-size: 10pt; text-align: justify">&nbsp;</TD>
      <TD STYLE="vertical-align: bottom; padding: 0.25pt 0.25pt 1pt; font-size: 10pt; text-align: justify"><A HREF="ea154559ex23-2_neuroonemedi.htm">Consent of Baker Tilly US, LLP</A></TD></TR>
    <TR>
      <TD STYLE="vertical-align: top; padding: 0.25pt">&nbsp;</TD>
      <TD STYLE="padding: 0.25pt">&nbsp;</TD>
      <TD STYLE="vertical-align: bottom; padding: 0.25pt">&nbsp;</TD></TR>
    <TR STYLE="background-color: #CCEEFF">
      <TD STYLE="vertical-align: top; padding: 0.25pt; font-size: 10pt">23.2</TD>
      <TD STYLE="padding: 0.25pt">&nbsp;</TD>
      <TD STYLE="vertical-align: bottom; padding: 0.25pt; font-size: 10pt; text-align: justify"><A HREF="ea154559ex5-1_neuroonemedi.htm">Consent of Honigman LLP (included in its opinion filed as Exhibit 5.1 to this Registration Statement)</A></TD></TR>
    <TR>
      <TD STYLE="vertical-align: top; padding: 0.25pt">&nbsp;</TD>
      <TD STYLE="padding: 0.25pt">&nbsp;</TD>
      <TD STYLE="vertical-align: bottom; padding: 0.25pt">&nbsp;</TD></TR>
    <TR STYLE="background-color: #CCEEFF">
      <TD STYLE="vertical-align: top; padding: 0.25pt; font-size: 10pt">24.1</TD>
      <TD STYLE="padding: 0.25pt">&nbsp;</TD>
      <TD STYLE="vertical-align: bottom; padding: 0.25pt 0.25pt 1pt; font-size: 10pt; text-align: justify"><A HREF="#a_001">Power of Attorney (included after the signature of the Registrant contained on Signature Page of this Registration Statement)</A></TD></TR>
    </TABLE>
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
  <TD STYLE="width: 0.25in; text-align: left">&dagger;</TD><TD STYLE="text-align: justify">Indicates management compensatory plan, contract or arrangement.</TD>
  </TR></TABLE>
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>
  
  <!-- Field: Page; Sequence: 5; Value: 1 -->
      <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
      <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
      <!-- Field: /Page -->
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="a_001"></A>SIGNATURES</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pursuant to the requirements of the Securities
  Act, the registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and
  has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Eden
  Prairie, State of Minnesota, on January 28, 2022.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
  
  <TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
    <TR STYLE="vertical-align: top">
      <TD>&nbsp;</TD>
      <TD COLSPAN="2" STYLE="font-size: 10pt"><B>NeuroOne Medical Technologies Corporation</B></TD></TR>
    <TR>
      <TD STYLE="width: 60%">&nbsp;</TD>
      <TD STYLE="width: 4%">&nbsp;</TD>
      <TD STYLE="width: 36%">&nbsp;</TD></TR>
    <TR>
      <TD>&nbsp;</TD>
      <TD STYLE="vertical-align: top; font-size: 10pt">By:</TD>
      <TD STYLE="border-bottom: black 1.5pt solid; vertical-align: top; font-size: 10pt">/s/ David Rosa</TD></TR>
    <TR>
      <TD>&nbsp;</TD>
      <TD STYLE="vertical-align: top">&nbsp;</TD>
      <TD STYLE="vertical-align: top; font-size: 10pt">David Rosa</TD></TR>
    <TR>
      <TD>&nbsp;</TD>
      <TD STYLE="vertical-align: top">&nbsp;</TD>
      <TD STYLE="vertical-align: top; font-size: 10pt"><I>President and Chief Executive Officer</I></TD></TR>
    </TABLE>
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>POWER OF ATTORNEY </B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Each person whose signature appears below constitutes
  and appoints David Rosa and Ronald McClurg, or either of them, as his or her true and lawful attorneys-in-fact and agents, with the full
  power of substitution and resubstitution, for him or her and in his or her name, place or stead, in any and all capacities, to sign any
  and all amendments to this Registration Statement (including post-effective amendments), and to file the same, with all exhibits thereto
  and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents,
  and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection
  therewith, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said
  attorneys-in-fact and agents, or any of them, or their or his or her substitute or substitutes, may lawfully do or cause to be done by
  virtue hereof.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pursuant to the requirements of the Securities
  Act, this Registration Statement on Form S-8 has been signed by the following persons in the capacities and on the dates indicated.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
  
  <TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
    <TR STYLE="vertical-align: top">
      <TD STYLE="border-bottom: black 1.5pt solid; width: 40%; font-size: 10pt; text-align: center"><B>Signature </B></TD>
      <TD STYLE="width: 1%">&nbsp;</TD>
      <TD STYLE="border-bottom: black 1.5pt solid; width: 37%; font-size: 10pt; text-align: center"><B>Title</B></TD>
      <TD STYLE="width: 1%">&nbsp;</TD>
      <TD STYLE="border-bottom: black 1.5pt solid; width: 21%; font-size: 10pt; text-align: center"><B>Date</B></TD></TR>
    <TR STYLE="vertical-align: top">
      <TD>&nbsp;</TD>
      <TD>&nbsp;</TD>
      <TD>&nbsp;</TD>
      <TD>&nbsp;</TD>
      <TD>&nbsp;</TD></TR>
    <TR>
      <TD STYLE="border-bottom: black 1.5pt solid; vertical-align: bottom; font-size: 10pt">/s/ David Rosa</TD>
      <TD STYLE="vertical-align: top">&nbsp;</TD>
      <TD STYLE="vertical-align: bottom; font-size: 10pt">President and Chief Executive Officer</TD>
      <TD STYLE="vertical-align: top">&nbsp;</TD>
      <TD STYLE="vertical-align: bottom; font-size: 10pt; text-align: center">January 28, 2022</TD></TR>
    <TR>
      <TD STYLE="vertical-align: bottom; font-size: 10pt">David Rosa</TD>
      <TD STYLE="vertical-align: top">&nbsp;</TD>
      <TD STYLE="vertical-align: top; font-size: 10pt">(Principal Executive Officer) and a Director</TD>
      <TD STYLE="vertical-align: top">&nbsp;</TD>
      <TD STYLE="vertical-align: top">&nbsp;</TD></TR>
    <TR>
      <TD STYLE="vertical-align: bottom">&nbsp;</TD>
      <TD STYLE="vertical-align: top">&nbsp;</TD>
      <TD STYLE="vertical-align: top">&nbsp;</TD>
      <TD STYLE="vertical-align: top">&nbsp;</TD>
      <TD STYLE="vertical-align: top">&nbsp;</TD></TR>
    <TR>
      <TD STYLE="border-bottom: black 1.5pt solid; vertical-align: bottom; font-size: 10pt">/s/ Ronald McClurg</TD>
      <TD STYLE="vertical-align: top">&nbsp;</TD>
      <TD STYLE="vertical-align: bottom; font-size: 10pt">Chief Financial Officer (Principal Financial </TD>
      <TD STYLE="vertical-align: top">&nbsp;</TD>
      <TD STYLE="vertical-align: bottom; font-size: 10pt; text-align: center">January 28, 2022</TD></TR>
    <TR>
      <TD STYLE="vertical-align: bottom; font-size: 10pt">Ronald McClurg</TD>
      <TD STYLE="vertical-align: top">&nbsp;</TD>
      <TD STYLE="vertical-align: top; font-size: 10pt">Officer and Principal Accounting Officer)</TD>
      <TD STYLE="vertical-align: top">&nbsp;</TD>
      <TD STYLE="vertical-align: top">&nbsp;</TD></TR>
    <TR STYLE="vertical-align: top">
      <TD>&nbsp;</TD>
      <TD>&nbsp;</TD>
      <TD>&nbsp;</TD>
      <TD>&nbsp;</TD>
      <TD>&nbsp;</TD></TR>
    <TR>
      <TD STYLE="border-bottom: black 1.5pt solid; vertical-align: top; font-size: 10pt">/s/ Paul Buckman</TD>
      <TD STYLE="vertical-align: top">&nbsp;</TD>
      <TD STYLE="vertical-align: top; font-size: 10pt">Director</TD>
      <TD STYLE="vertical-align: top">&nbsp;</TD>
      <TD STYLE="vertical-align: bottom; font-size: 10pt; text-align: center">January 28, 2022</TD></TR>
    <TR STYLE="vertical-align: top">
      <TD STYLE="font-size: 10pt">Paul Buckman</TD>
      <TD>&nbsp;</TD>
      <TD>&nbsp;</TD>
      <TD>&nbsp;</TD>
      <TD>&nbsp;</TD></TR>
    <TR STYLE="vertical-align: top">
      <TD>&nbsp;</TD>
      <TD>&nbsp;</TD>
      <TD>&nbsp;</TD>
      <TD>&nbsp;</TD>
      <TD>&nbsp;</TD></TR>
    <TR>
      <TD STYLE="border-bottom: black 1.5pt solid; vertical-align: top; font-size: 10pt">/s/ Jeffrey Mathiesen</TD>
      <TD STYLE="vertical-align: top">&nbsp;</TD>
      <TD STYLE="vertical-align: top; font-size: 10pt">Director</TD>
      <TD STYLE="vertical-align: top">&nbsp;</TD>
      <TD STYLE="vertical-align: bottom; font-size: 10pt; text-align: center">January 28, 2022</TD></TR>
    <TR STYLE="vertical-align: top">
      <TD STYLE="font-size: 10pt">Jeffrey Mathiesen</TD>
      <TD>&nbsp;</TD>
      <TD>&nbsp;</TD>
      <TD>&nbsp;</TD>
      <TD>&nbsp;</TD></TR>
    <TR STYLE="vertical-align: top">
      <TD>&nbsp;</TD>
      <TD>&nbsp;</TD>
      <TD>&nbsp;</TD>
      <TD>&nbsp;</TD>
      <TD>&nbsp;</TD></TR>
    <TR>
      <TD STYLE="border-bottom: black 1.5pt solid; vertical-align: top; font-size: 10pt">/s/ Edward Andrle</TD>
      <TD STYLE="vertical-align: top">&nbsp;</TD>
      <TD STYLE="vertical-align: top; font-size: 10pt">Director</TD>
      <TD STYLE="vertical-align: top">&nbsp;</TD>
      <TD STYLE="vertical-align: bottom; font-size: 10pt; text-align: center">January 28, 2022</TD></TR>
    <TR STYLE="vertical-align: top">
      <TD STYLE="font-size: 10pt">Edward Andrle</TD>
      <TD>&nbsp;</TD>
      <TD>&nbsp;</TD>
      <TD>&nbsp;</TD>
      <TD>&nbsp;</TD></TR>
    </TABLE>
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">II-3</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>
  
  <!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>
  
  </BODY>
  </HTML>
metadata_documents: [{"type": "S-8", "sequence": "1", "filename": "ea154559-s8_neuroonemedical.htm", "description": "REGISTRATION STATEMENT", "secsgml_size_bytes": 43495}]
metadata_filer: {"company-data": {"conformed-name": "NEUROONE MEDICAL TECHNOLOGIES Corp", "cik": "0001500198", "assigned-sic": "3841", "irs-number": "270863354", "state-of-incorporation": "DE", "fiscal-year-end": "0930"}, "filing-values": {"form-type": "S-8", "act": "33", "file-number": "333-262397", "film-number": "22568974"}, "business-address": {"street1": "7599 ANAGRAM DR", "city": "EDEN PRAIRIE", "state": "MN", "zip": "55344", "phone": "(952) 426-1383"}, "mail-address": {"street1": "7599 ANAGRAM DR", "city": "EDEN PRAIRIE", "state": "MN", "zip": "55344"}, "former-company": {"former-conformed-name": "Original Source Entertainment, Inc.", "date-changed": "20100830"}}
text: As filed with the Securities and Exchange Commission on January 28, 2022
  Registration No. 333-
  UNITED STATES
  SECURITIES AND EXCHANGE COMMISSION
  Washington, D.C. 20549
  FORM S-8
  REGISTRATION STATEMENT
  UNDER
  THE SECURITIES ACT OF 1933
  NeuroOne
  Medical Technologies Corporation
  (Exact name of registrant as specified in its charter)
  Delaware
  27-0863354
  (State or other jurisdiction of
  incorporation or organization)
  (I.R.S. Employer
  Identification Number.)
  7599 Anagram Dr.,
  Eden Prairie, MN
  55344
  (Address of principal executive offices)
  (Zip code)
  NeuroOne Medical Technologies Corporation 2017
      Equity Incentive Plan
  (Full title of the plan)
  David Rosa
  President and Chief Executive Officer
  NeuroOne Medical Technologies Corporation
  7599 Anagram Dr.,
  Eden Prairie, MN 55344
  952-426-1383
  (Name, address,
      and telephone number, including area code, of agent for service)
  Copy to:
  Phillip D. Torrence, Esq.
  Emily Johns, Esq.
  Honigman LLP
  650 Trade Center Way, Suite 200
  Kalamazoo, Michigan 49002-0402
  (269) 337-7700
  Indicate by check mark whether the registrant
  is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company.
  See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company,"
  and "emerging growth company" in Rule 12b-2 of the Exchange Act.
  Large accelerated filer
  ☐
  Accelerated filer
  ☐
  Non-accelerated filer
  ☒
  Smaller reporting company
  ☒
  Emerging growth company
  ☐
  If an emerging growth company, indicate by check
  mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting
  standards provided pursuant to Section 7(a)(2)(B) of the Securities Act.
  ☐
  CALCULATION OF REGISTRATION FEE
  Title of securities to be registered
  Amount to be
  registered(1)
  Proposed maximum
  offering price
  per share
  Proposed maximum
  aggregate offering
  price
  Amount of
  registration
  fee
  Common stock, $0.001 par value per share
  NeuroOne Medical Technologies Corporation 2017 Equity Incentive Plan(2)
  1,616,873
  $
  1.94
  (3)
  $
  3,136,733.62
  (3)
  $
  290.78
  (1)
  Pursuant to Rule 416(a) promulgated under the Securities Act of 1933, as amended, (the
  "Securities Act"
  ), this Registration Statement shall also cover any additional shares of Registrant's common stock that become issuable under the plan set forth herein by reason of any stock dividend, stock split, reclassification, recapitalization, spin-off or other similar transaction effected without receipt of consideration that increases the number of outstanding shares of Registrant's common stock, as applicable.
  (2)
  Represents shares of common stock available for future issuance under the Registrant's 2017 Equity Incentive Plan.
  (3)
  Estimated solely for the purpose of calculating the amount of the registration fee pursuant to Rule 457(c) and Rule 457(h) under the Securities Act. The offering price per share and aggregate offering price are based on the average of the high and low prices of the Registrant's common stock as reported on the Nasdaq Capital Market on January 26, 2022.
  EXPLANATORY NOTE
  This Registration Statement on Form S-8 is
  being filed by NeuroOne Medical Technologies Corporation, a Delaware corporation (the
  "Company,"
  the
  "Registrant
  ,
  "
  "we
  ,
  " "us
  ,
  " or "our"
  ), relating to 1,616,873 shares of its common
  stock, par value $0.001 per share (the
  "Common Stock"
  ), issuable pursuant to the 2017 Equity Incentive Plan
  (the "
  2017 Equity Incentive Plan
  "). The Common Stock being registered hereunder is in addition to the (i) 1,300,000
  shares of Common Stock registered on the Registrant's Form S-8 previously filed with the Securities and Exchange
  Commission (the "
  Commission
  ") on
  May 1, 2018
  (Commission File No. 333-224572) and (ii) 1,079,835
  shares of Common Stock registered on the Registrant's Form S-8 previously filed with the Commission on
  November 23, 2021
  (Commission File No. 333-261302) (collectively, the "
  Prior Registration Statements
  ").
  This Registration Statement relates to securities
  of the same class as that to which the Prior Registration Statements relate, and is submitted in accordance with General Instruction E
  to Form S-8 regarding the registration of additional securities. Pursuant to such instruction, the contents of the Prior Registration
  Statements are incorporated herein by reference and made part of this Registration Statement, except as amended hereby.
  PART II
  INFORMATION REQUIRED IN THE REGISTRATION STATEMENT
  Item 3. Incorporation of Documents by Reference.
  Pursuant to General Instruction
  E to Form S-8, the contents of the Prior Registration Statements are incorporated herein by reference.
  The following documents filed
  with the Commission by the Registrant are hereby incorporated by reference in this Registration Statement:
  (a)
  our Annual Report on Form 10-K for the year ended September
  30, 2021 filed with the Commission on
  December 15, 2021
  ;
  (b)
  our Current Reports on Form 8-K filed with the Commission
  on
  October 4, 2021
  and
  October 14, 2021
  ; and
  (c)
  the description of our Common Stock in our registration statement
  on
  Form 8-A
  filed with the SEC on May 25, 2021 and as amended by any subsequent amendment or report filed for the purpose of updating
  such description.
  In addition, all documents
  the Registrant subsequently files pursuant to Sections 13(a), 13(c), 14 or 15(d) of the Securities Exchange Act of 1934, as amended (the
  "Exchange Act"
  ), after the filing of this Registration Statement and prior to the filing of a post-effective
  amendment which indicates that all securities offered hereby have been sold or which deregisters all securities covered hereby then remaining
  unsold are incorporated by reference in this Registration Statement and are a part hereof from the date of filing of such documents. Notwithstanding
  anything herein, the Registrant is not incorporating by reference any information furnished under Item 2.02 or Item 7.01 of any Current
  Report on Form 8-K, unless, and to the extent, specified in any such Current Report on Form 8-K.
  Any statement herein or contained
  in a document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded for purposes
  of this Registration Statement to the extent that a statement contained herein, or in any subsequently filed document, which also is or
  is deemed to be incorporated by reference herein, modifies or supersedes such prior statement. Any such statement so modified or superseded
  shall not be deemed, except as so modified or superseded, to constitute part of this Registration Statement.
  II-
  1
  Item 8. Exhibits.
  EXHIBIT INDEX
  The following exhibits are filed as part of this
  registration statement.
  INDEX TO EXHIBITS
  Exhibit
  Number
  Description
  4.1
  Certificate of Incorporation of NeuroOne Medical Technologies Corporation (incorporated by reference to Exhibit 3.4 on the Registrant's Current Report on Form 8-K filed on June, 29, 2017)
  4.2
  Certificate of Amendment to Amended and Restated Certificate of Incorporation of NeuroOne Medical Technologies Corporation (incorporated by reference to Exhibit 3.1 on the Registrant's Current Report on Form 8-K filed on March 31, 2021)
  4.3
  Bylaws of NeuroOne Medical Technologies Corporation (incorporated by reference to Exhibit 3.5 on the Registrant's Current Report on Form 8-K filed on June 29, 2017)
  4.4†
  2017 Equity Incentive Plan (incorporated by reference to Appendix G to Schedule 14C filed on April 20, 2017).
  5.1
  Opinion of Honigman LLP
  23.1
  Consent of BDO USA, LLP
  23.2
  Consent of Baker Tilly US, LLP
  23.2
  Consent of Honigman LLP (included in its opinion filed as Exhibit 5.1 to this Registration Statement)
  24.1
  Power of Attorney (included after the signature of the Registrant contained on Signature Page of this Registration Statement)
  †
  Indicates management compensatory plan, contract or arrangement.
  II-
  2
  SIGNATURES
  Pursuant to the requirements of the Securities
  Act, the registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and
  has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Eden
  Prairie, State of Minnesota, on January 28, 2022.
  NeuroOne Medical Technologies Corporation
  By:
  /s/ David Rosa
  David Rosa
  President and Chief Executive Officer
  POWER OF ATTORNEY
  Each person whose signature appears below constitutes
  and appoints David Rosa and Ronald McClurg, or either of them, as his or her true and lawful attorneys-in-fact and agents, with the full
  power of substitution and resubstitution, for him or her and in his or her name, place or stead, in any and all capacities, to sign any
  and all amendments to this Registration Statement (including post-effective amendments), and to file the same, with all exhibits thereto
  and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents,
  and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection
  therewith, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said
  attorneys-in-fact and agents, or any of them, or their or his or her substitute or substitutes, may lawfully do or cause to be done by
  virtue hereof.
  Pursuant to the requirements of the Securities
  Act, this Registration Statement on Form S-8 has been signed by the following persons in the capacities and on the dates indicated.
  Signature
  Title
  Date
  /s/ David Rosa
  President and Chief Executive Officer
  January 28, 2022
  David Rosa
  (Principal Executive Officer) and a Director
  /s/ Ronald McClurg
  Chief Financial Officer (Principal Financial
  January 28, 2022
  Ronald McClurg
  Officer and Principal Accounting Officer)
  /s/ Paul Buckman
  Director
  January 28, 2022
  Paul Buckman
  /s/ Jeffrey Mathiesen
  Director
  January 28, 2022
  Jeffrey Mathiesen
  /s/ Edward Andrle
  Director
  January 28, 2022
  Edward Andrle
  II-3